The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Ten large-cap stocks, including CRWV, COHR & AMZN, were the worst performers last week. Weak results, downgrades, and FTC ...

Hims & Hers Health (NYSE: HIMS), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

In its updated report, Hims & Hers Health, Inc. (NYSE:HIMS) said revenues increased by 73 percent to $544.8 million from $315 ...